Three New Treatments for Osteoarthritis: Updates From ACR 2018

Oct 26, 2018

Late-breaking abstracts presented at ACR 2018 detail 3 promising options: a novel non-opioid analgesic and 2 disease-modifying OA drugs.

References1. Schnitzer TJ, Easton R, Pang S, et al. Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee [Abstract L20]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 26, 2018.2. McGuire D, Segal N, Metyas S, et al. Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness [Abstract L16]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 26, 2018.3. Yazici Y, McAlindon TE, Gibofsky A, et al. Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee [Abstract L03]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 26, 2018.This information is brought to you by Rheumatology Network and is not sponsored by, nor a part of, the American College of Rheumatology.